This study is designed to observe clinical outcomes in patients receiving the PROMUS Element
Plus Everolimus-Eluting Platinum Chromium Coronary Stent System in routine clinical practice.
Patients will have symptomatic heart disease or documented silent ischemia. This is a
prospective, open-label consecutively-enrolling study. Clinical follow-up is through 5 years.
Approximately 2,689 patients are to be enrolled in up to 65 centers in the United States.